NO323987B1 - Farmasoytisk sammensetning og produkt omfattende atorvastatin, anvendelse derav, samt sett - Google Patents

Farmasoytisk sammensetning og produkt omfattende atorvastatin, anvendelse derav, samt sett Download PDF

Info

Publication number: NO323987B1
Authority: NO; Norway
Prior art keywords: pharmaceutically acceptable; acceptable salt; atorvastatin; individual; ace inhibitor
Prior art date: 1997-08-29

Application number

NO20000996A

Other languages

English (en)

Norwegian (no)

Other versions

NO20000996D0 (no

NO20000996L (no

Inventor

Robert Andrew Donald Scott

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-29

Filing date

2000-02-28

Publication date

2007-07-30

2000-02-28 Application filed by Pfizer filed Critical Pfizer

2000-02-28 Publication of NO20000996D0 publication Critical patent/NO20000996D0/no

2000-04-27 Publication of NO20000996L publication Critical patent/NO20000996L/no

2007-07-30 Publication of NO323987B1 publication Critical patent/NO323987B1/no

Links

XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title claims description 45
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title claims description 45
229960005370 atorvastatin Drugs 0.000 title claims description 45
239000008194 pharmaceutical composition Substances 0.000 title claims description 9
239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
150000003839 salts Chemical class 0.000 claims description 74
238000011282 treatment Methods 0.000 claims description 27
206010002383 Angina Pectoris Diseases 0.000 claims description 23
206010020772 Hypertension Diseases 0.000 claims description 23
208000031226 Hyperlipidaemia Diseases 0.000 claims description 22
239000000203 mixture Substances 0.000 claims description 22
201000001320 Atherosclerosis Diseases 0.000 claims description 21
230000000747 cardiac effect Effects 0.000 claims description 21
150000001875 compounds Chemical class 0.000 claims description 21
239000003814 drug Substances 0.000 claims description 19
229940079593 drug Drugs 0.000 claims description 16
239000005541 ACE inhibitor Substances 0.000 claims description 14
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 14
239000003085 diluting agent Substances 0.000 claims description 12
239000002552 dosage form Substances 0.000 claims description 11
239000003937 drug carrier Substances 0.000 claims description 10
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 9
229960003401 ramipril Drugs 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 8
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 7
XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 7
108010061435 Enalapril Proteins 0.000 claims description 7
108010007859 Lisinopril Proteins 0.000 claims description 7
229960004530 benazepril Drugs 0.000 claims description 7
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 7
229960000830 captopril Drugs 0.000 claims description 7
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 7
229960000873 enalapril Drugs 0.000 claims description 7
229960002490 fosinopril Drugs 0.000 claims description 7
229960002394 lisinopril Drugs 0.000 claims description 7
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 7
229960001455 quinapril Drugs 0.000 claims description 7
VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 6
229960002582 perindopril Drugs 0.000 claims description 6
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
229960002051 trandolapril Drugs 0.000 claims description 6
206010003210 Arteriosclerosis Diseases 0.000 claims description 4
208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
229940127557 pharmaceutical product Drugs 0.000 claims description 2
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 3
239000002220 antihypertensive agent Substances 0.000 description 32
229940030600 antihypertensive agent Drugs 0.000 description 31
208000029078 coronary artery disease Diseases 0.000 description 27
239000002253 acid Substances 0.000 description 19
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 15
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 15
229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 13
230000000694 effects Effects 0.000 description 13
238000012216 screening Methods 0.000 description 12
238000012360 testing method Methods 0.000 description 11
239000002934 diuretic Substances 0.000 description 10
230000001882 diuretic effect Effects 0.000 description 10
239000012458 free base Substances 0.000 description 10
150000002632 lipids Chemical class 0.000 description 10
229960000528 amlodipine Drugs 0.000 description 9
238000002604 ultrasonography Methods 0.000 description 8
OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 7
241000282412 Homo Species 0.000 description 7
229960001770 atorvastatin calcium Drugs 0.000 description 7
230000036772 blood pressure Effects 0.000 description 7
230000007211 cardiovascular event Effects 0.000 description 7
235000005911 diet Nutrition 0.000 description 7
230000037213 diet Effects 0.000 description 7
238000000034 method Methods 0.000 description 7
108010010234 HDL Lipoproteins Proteins 0.000 description 6
102000015779 HDL Lipoproteins Human genes 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
229960004005 amlodipine besylate Drugs 0.000 description 6
238000004364 calculation method Methods 0.000 description 6
125000002091 cationic group Chemical group 0.000 description 6
238000002586 coronary angiography Methods 0.000 description 6
238000007726 management method Methods 0.000 description 6
108010028554 LDL Cholesterol Proteins 0.000 description 5
108010007622 LDL Lipoproteins Proteins 0.000 description 5
102000007330 LDL Lipoproteins Human genes 0.000 description 5
239000003524 antilipemic agent Substances 0.000 description 5
239000000480 calcium channel blocker Substances 0.000 description 5
210000001715 carotid artery Anatomy 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
230000003902 lesion Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
229940127291 Calcium channel antagonist Drugs 0.000 description 4
208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 4
229910002651 NO3 Inorganic materials 0.000 description 4
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
239000000006 Nitroglycerin Substances 0.000 description 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
230000003276 anti-hypertensive effect Effects 0.000 description 4
230000003143 atherosclerotic effect Effects 0.000 description 4
-1 cationic salts Chemical class 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
238000011161 development Methods 0.000 description 4
229960003711 glyceryl trinitrate Drugs 0.000 description 4
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 4
230000010412 perfusion Effects 0.000 description 4
239000000902 placebo Substances 0.000 description 4
229940068196 placebo Drugs 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000000391 smoking effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
239000002585 base Substances 0.000 description 3
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 3
210000004351 coronary vessel Anatomy 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
238000002651 drug therapy Methods 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002107 myocardial effect Effects 0.000 description 3
208000031225 myocardial ischemia Diseases 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
241000894007 species Species 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
229940124549 vasodilator Drugs 0.000 description 3
239000003071 vasodilator agent Substances 0.000 description 3
CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
230000002411 adverse Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000003257 anti-anginal effect Effects 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
238000003556 assay Methods 0.000 description 2
SHZPNDRIDUBNMH-NIJVSVLQSA-L atorvastatin calcium trihydrate Chemical compound O.O.O.[Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 SHZPNDRIDUBNMH-NIJVSVLQSA-L 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
150000007658 benzothiadiazines Chemical class 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000003218 coronary vasodilator agent Substances 0.000 description 2
239000006184 cosolvent Substances 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000035487 diastolic blood pressure Effects 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
229940043237 diethanolamine Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 2
239000000890 drug combination Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
229940002661 lipitor Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
235000019371 penicillin G benzathine Nutrition 0.000 description 2
239000000810 peripheral vasodilating agent Substances 0.000 description 2
229960002116 peripheral vasodilator Drugs 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229960005141 piperazine Drugs 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229960002965 pravastatin Drugs 0.000 description 2
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
229960002855 simvastatin Drugs 0.000 description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
238000009662 stress testing Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
229960000281 trometamol Drugs 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
LTSOENFXCPOCHG-GQCTYLIASA-N 4-chloro-6-[[(e)-3-oxobut-1-enyl]amino]-1-n-prop-2-enylbenzene-1,3-disulfonamide Chemical compound CC(=O)\C=C\NC1=CC(Cl)=C(S(N)(=O)=O)C=C1S(=O)(=O)NCC=C LTSOENFXCPOCHG-GQCTYLIASA-N 0.000 description 1
BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
VGLGVJVUHYTIIU-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3-[(prop-2-enylthio)methyl]-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(CSCC=C)NS2(=O)=O VGLGVJVUHYTIIU-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000272522 Anas Species 0.000 description 1
101150102415 Apob gene Proteins 0.000 description 1
206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
239000002083 C09CA01 - Losartan Substances 0.000 description 1
239000004072 C09CA03 - Valsartan Substances 0.000 description 1
RZZPDXZPRHQOCG-OJAKKHQRSA-M CDP-choline(1-) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010071200 Carbohydrate intolerance Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000014882 Carotid artery disease Diseases 0.000 description 1
206010008479 Chest Pain Diseases 0.000 description 1
229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 description 1
KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
208000032928 Dyslipidaemia Diseases 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
238000008214 LDL Cholesterol Methods 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
201000001068 Prinzmetal angina Diseases 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
208000007718 Stable Angina Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
229960000571 acetazolamide Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000011256 aggressive treatment Methods 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
229950007522 altizide Drugs 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
NSFYKDVWNTWJOK-UHFFFAOYSA-K aluminum;pyridine-3-carboxylate Chemical compound [Al+3].[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1.[O-]C(=O)C1=CC=CN=C1 NSFYKDVWNTWJOK-UHFFFAOYSA-K 0.000 description 1
229950007019 ambuside Drugs 0.000 description 1
XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
229960002576 amiloride Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
IIOPLILENRZKRV-UHFFFAOYSA-N azosemide Chemical compound C=1C=CSC=1CNC=1C=C(Cl)C(S(=O)(=O)N)=CC=1C1=NN=N[N]1 IIOPLILENRZKRV-UHFFFAOYSA-N 0.000 description 1
229960004988 azosemide Drugs 0.000 description 1
YTLQFZVCLXFFRK-UHFFFAOYSA-N bendazol Chemical compound N=1C2=CC=CC=C2NC=1CC1=CC=CC=C1 YTLQFZVCLXFFRK-UHFFFAOYSA-N 0.000 description 1
229960003515 bendroflumethiazide Drugs 0.000 description 1
HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
229960004411 benziodarone Drugs 0.000 description 1
CZCHIEJNWPNBDE-UHFFFAOYSA-N benziodarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(O)C(I)=C1 CZCHIEJNWPNBDE-UHFFFAOYSA-N 0.000 description 1
NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
229960001541 benzthiazide Drugs 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
229960004536 betahistine Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
229960004064 bumetanide Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
230000036996 cardiovascular health Effects 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000011976 chest X-ray Methods 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
229960000876 cinnarizine Drugs 0.000 description 1
229960001284 citicoline Drugs 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000008602 contraction Effects 0.000 description 1
208000026758 coronary atherosclerosis Diseases 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000001434 dietary modification Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960001389 doxazosin Drugs 0.000 description 1
RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
SLFUXNFVAANERW-UHFFFAOYSA-N ethyl hexanoate;potassium Chemical compound [K].CCCCCC(=O)OCC SLFUXNFVAANERW-UHFFFAOYSA-N 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960003580 felodipine Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000007446 glucose tolerance test Methods 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000002657 hormone replacement therapy Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
229960000201 isosorbide dinitrate Drugs 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
229960003827 isosorbide mononitrate Drugs 0.000 description 1
229960004427 isradipine Drugs 0.000 description 1
229960004340 lacidipine Drugs 0.000 description 1
GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
150000002596 lactones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229960004773 losartan Drugs 0.000 description 1
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960003194 meglumine Drugs 0.000 description 1
AXLHVTKGDPVANO-UHFFFAOYSA-N methyl 2-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound COC(=O)C(N)CNC(=O)OC(C)(C)C AXLHVTKGDPVANO-UHFFFAOYSA-N 0.000 description 1
VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960001783 nicardipine Drugs 0.000 description 1
229960000715 nimodipine Drugs 0.000 description 1
229960000227 nisoldipine Drugs 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229960005425 nitrendipine Drugs 0.000 description 1
238000010606 normalization Methods 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000036581 peripheral resistance Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
230000002028 premature Effects 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
235000021003 saturated fats Nutrition 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000003325 tomography Methods 0.000 description 1
235000021076 total caloric intake Nutrition 0.000 description 1
230000008733 trauma Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960002906 trimazosin Drugs 0.000 description 1
YNZXWQJZEDLQEG-UHFFFAOYSA-N trimazosin Chemical compound N1=C2C(OC)=C(OC)C(OC)=CC2=C(N)N=C1N1CCN(C(=O)OCC(C)(C)O)CC1 YNZXWQJZEDLQEG-UHFFFAOYSA-N 0.000 description 1
235000021081 unsaturated fats Nutrition 0.000 description 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
229960004699 valsartan Drugs 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Diabetes (AREA)
Obesity (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyrrole Compounds (AREA)
Iron Core Of Rotating Electric Machines (AREA)

NO20000996A 1997-08-29 2000-02-28 Farmasoytisk sammensetning og produkt omfattende atorvastatin, anvendelse derav, samt sett NO323987B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5727697P	1997-08-29	1997-08-29
PCT/IB1998/001230 WO1999011260A1 (fr)	1997-08-29	1998-08-11	Therapie combinee utilisant de l'atorvastatine et un antihypertenseur

Publications (3)

Publication Number	Publication Date
NO20000996D0 NO20000996D0 (no)	2000-02-28
NO20000996L NO20000996L (no)	2000-04-27
NO323987B1 true NO323987B1 (no)	2007-07-30

Family

ID=22009602

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20000996A NO323987B1 (no)	1997-08-29	2000-02-28	Farmasoytisk sammensetning og produkt omfattende atorvastatin, anvendelse derav, samt sett

Country Status (41)

Country	Link
US (2)	US20020099046A1 (fr)
EP (1)	EP1009400B1 (fr)
JP (2)	JP2001514223A (fr)
KR (3)	KR20010022477A (fr)
CN (3)	CN1473567A (fr)
AP (1)	AP1191A (fr)
AR (1)	AR016399A1 (fr)
AT (1)	ATE285767T1 (fr)
AU (1)	AU740424B2 (fr)
BG (1)	BG64724B1 (fr)
BR (1)	BR9811556A (fr)
CA (1)	CA2296723A1 (fr)
CO (1)	CO4970724A1 (fr)
DE (1)	DE69828413T2 (fr)
DZ (1)	DZ2595A1 (fr)
EA (1)	EA200000012A1 (fr)
EG (1)	EG24678A (fr)
ES (1)	ES2234134T3 (fr)
GT (1)	GT199800126A (fr)
HR (1)	HRP980474A2 (fr)
HU (1)	HUP0004318A3 (fr)
ID (1)	ID24118A (fr)
IL (2)	IL133962A0 (fr)
IS (1)	IS5341A (fr)
MA (1)	MA26536A1 (fr)
MY (1)	MY121008A (fr)
NO (1)	NO323987B1 (fr)
NZ (2)	NZ502280A (fr)
OA (1)	OA11291A (fr)
PA (1)	PA8457901A1 (fr)
PE (1)	PE107099A1 (fr)
PL (1)	PL339091A1 (fr)
PT (1)	PT1009400E (fr)
SA (1)	SA98190603B1 (fr)
SK (1)	SK1432000A3 (fr)
TN (1)	TNSN98155A1 (fr)
TR (1)	TR200000563T2 (fr)
UY (1)	UY25155A1 (fr)
WO (1)	WO1999011260A1 (fr)
YU (1)	YU2000A (fr)
ZA (1)	ZA987839B (fr)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0656786B2 (fr)	1992-05-19	2014-04-23	Novogen Research Pty Ltd	Utilisation d'extraits des phyto-estrogenes d'isoflavones à partir de soja ou de trèfle
US6262277B1 (en)	1994-09-13	2001-07-17	G.D. Searle And Company	Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en)	1994-09-13	2003-11-04	G.D. Searle & Co.	Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AUPO203996A0 (en)	1996-08-30	1996-09-26	Novogen Research Pty Ltd	Therapeutic uses
GT199800127A (es) *	1997-08-29	2000-02-01		Combinaciones terapeuticas.
EP1063991A1 (fr) *	1998-03-17	2001-01-03	Warner-Lambert Company Llc	Associations statine-inhibiteur de metalloprotease matricielle
WO2000038721A1 (fr)	1998-12-23	2000-07-06	G.D. Searle Llc	Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
AU2007200367B2 (en) *	1999-02-06	2010-04-08	Astrazeneca Ab	Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
DK1216038T3 (da)	1999-08-30	2005-12-27	Sanofi Aventis Deutschland	Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AUPQ266199A0 (en)	1999-09-06	1999-09-30	Novogen Research Pty Ltd	Compositions and therapeutic methods involving isoflavones and analogues thereof
DE19944803A1 (de) *	1999-09-20	2001-03-29	Bayer Ag	Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
WO2001022976A2 (fr)	1999-09-24	2001-04-05	Vasogen Ireland Limited	Polytherapie destinee au traitement de l'atherosclerose
FR2803525B1 (fr) *	2000-01-06	2002-05-03	Sod Conseils Rech Applic	Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle
AR030414A1 (es) *	2000-04-03	2003-08-20	Astrazeneca Ab	Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en)	2000-04-10	2001-10-17	Nicholas J Wald	Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) *	2000-06-22	2000-06-22	Astrazeneca Ab	New formulation
AR032758A1 (es)	2000-07-19	2003-11-26	Novartis Ag	Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos
AU2001284413A1 (en) *	2000-08-30	2002-03-13	Sankyo Company Limited	Medicinal compositions for preventing or treating heart failure
US7018649B2 (en) *	2000-10-23	2006-03-28	Euro-Celtique, S.A.	Felodipine transdermal device and methods
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
AUPR255401A0 (en) *	2001-01-16	2001-02-08	Novogen Research Pty Ltd	Regulation of lipids and/or bone density and compositions therefor
HU230253B1 (hu)	2001-01-26	2015-11-30	Merck Sharp & Dohme Corp	Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en)	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
DK1355644T3 (da)	2001-01-26	2006-10-23	Schering Corp	Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
AUPR363301A0 (en)	2001-03-08	2001-04-05	Novogen Research Pty Ltd	Dimeric isoflavones
US20030149010A1 (en) *	2001-07-19	2003-08-07	Keller Bradley T.	Combination of an aldosterone receptor antagonist and an HMG CoA reductase inhibitor
PE20030324A1 (es) *	2001-07-31	2003-04-03	Warner Lambert Co	Composiciones farmaceuticas de amlodipina y atorvastatina
US6852737B2 (en) *	2001-08-06	2005-02-08	Recordati Ireland Limited	Crude and crystalline forms of lercanidipine hydrochloride
US7053080B2 (en)	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en)	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
JP2005504091A (ja)	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
US8101209B2 (en)	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6852753B2 (en)	2002-01-17	2005-02-08	Pharmacia Corporation	Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
CA2490636A1 (fr) *	2002-06-20	2003-12-31	The Governors Of The University Of Alberta	Dichloroacetate en combinaison avec des medicaments cardioprotecteurs ou hemodynamiques
JP2005533822A (ja) *	2002-06-27	2005-11-10	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	臭化水素酸カルベジロール
MXPA04012923A (es) *	2002-06-27	2005-03-31	Sb Pharmco Inc	Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0221579D0 (en) *	2002-09-17	2002-10-23	Pfizer Ltd	Combinations of atorvastatin and, adrenergic receptor antagonists
JP2006504800A (ja) *	2002-10-16	2006-02-09	レコーダチアイルランドリミテッド	リシノプリル／レルカニジピンの組み合わせ治療
WO2004043457A1 (fr)	2002-11-06	2004-05-27	Schering Corporation	Inhibiteurs d'absorption de cholesterol pour le traitement de troubles auto-immuns
JP4589919B2 (ja)	2003-03-07	2010-12-01	シェーリングコーポレイション	高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja)	2003-03-07	2006-08-31	シェーリング　コーポレイション	置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517571C (fr)	2003-03-07	2011-07-05	Schering Corporation	Azetidinones substituees , procedes pour leur preparation, formulations et utilisations de celles-ci
GB0322552D0 (en)	2003-09-26	2003-10-29	Astrazeneca Uk Ltd	Therapeutic treatment
EP1686967A4 (fr) *	2003-11-25	2012-08-08	Smithkline Beecham Cork Ltd	Base libre de carvedilol, ses sels, formes anhydres ou solvats, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et methodes de traitement ou d'administration
CA2547137A1 (fr) *	2003-11-25	2005-06-09	Sb Pharmco Puerto Rico Inc.	Base libre de carvedilol, ses sels, formes anhydres ou solvates, compositions pharmaceutiques correspondantes, formulations a liberation controlee, et procedes de traitement ou d'administration
JP2007512372A (ja) *	2003-11-25	2007-05-17	エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド	カルベジロール塩、対応する組成物、送達および／または治療方法
KR20050092519A (ko) *	2004-03-16	2005-09-22	화이자 인코포레이티드	아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합
US20070191438A1 (en) *	2004-04-06	2007-08-16	Rohrer Susan P	Methods for the treatment of hypertension
DE602005025755D1 (de)	2004-06-04	2011-02-17	Teva Pharma	Irbesartan enthaltende pharmazeutische zusammensetzung
ES2342090T3 (es) *	2004-08-25	2010-07-01	Essentialis, Inc.	Formulaciones farmaceuticas de agentes de apertura de canales de potasio dependientes de atp y usos de los mismos.
BRPI0607142A2 (pt) *	2005-02-17	2009-08-11	Chiesi Farma Spa	combinações terapêuticas de manidipina e uma estatina, seu uso e um kit
EP2000137B1 (fr) *	2006-03-29	2015-10-21	Kowa Company, Ltd.	Agent favorisant la baisse des triglycérides et agent améliorant l'hyperinsulinisme
US8642083B2 (en) *	2006-10-30	2014-02-04	Hanall Biopharma Co., Ltd.	Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
KR101209319B1 (ko)	2008-04-29	2012-12-06	한올바이오파마주식회사	안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
CZ2008740A3 (cs) *	2008-11-24	2010-01-06	Zentiva, A.S.	Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
MA33056B1 (fr) *	2009-01-23	2012-02-01	Hanmi Holding Co Ltd	Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
SI23149A (sl) *	2009-09-21	2011-03-31	Silverstone Pharma	Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni
RU2481124C1 (ru) *	2011-10-27	2013-05-10	Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ"	Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения
CN102671198A (zh) *	2011-12-17	2012-09-19	东莞达信生物技术有限公司	一种降压降脂复方药及其制备方法
KR20140028971A (ko) *	2012-08-31	2014-03-10	한미약품 주식회사	아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
JP2016514125A (ja) *	2013-03-12	2016-05-19	エルジー・ライフ・サイエンシーズ・リミテッドＬＧＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	バルサルタン及びロスバスタチンカルシウムを含む複合製剤及びその製造方法
CN104173420A (zh) *	2013-05-20	2014-12-03	广州诺氏刘生物科技有限公司	一种治疗急性肾衰竭的药物
US10537546B2 (en)	2014-10-23	2020-01-21	Arena Pharmaceuticals, Inc.	Method of treating conditions related to the PGI2 receptor
RU2724338C2 (ru) *	2015-06-30	2020-06-23	Ханми Фарм. Ко., Лтд.	Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин
FR3040303B1 (fr) *	2015-08-27	2019-04-05	Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger	Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
CN105232555A (zh) *	2015-11-19	2016-01-13	哈尔滨圣吉药业股份有限公司	一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法
AU2017274438A1 (en) *	2016-06-02	2018-12-13	Ana Pharmaceuticals, Inc.	Methods and compositions for treatment of hypercalciuria and nephrolithiasis
SI4101454T1 (sl)	2017-01-25	2024-10-30	The George Institute for Global Health	Sestavki za uporabo pri zdravljenju hipertenzije
US12521380B2 (en)	2017-01-25	2026-01-13	The George Institute for Global Health	Compositions for the treatment of hypertension
IL268997B2 (en)	2017-03-01	2023-09-01	Arena Pharm Inc	Preparations containing pgi2 receptor agonists and processes for their preparation
EP3796902A1 (fr)	2018-05-16	2021-03-31	Arena Pharmaceuticals, Inc.	Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés
AU2019309329B2 (en) *	2018-07-26	2025-01-30	The George Institute for Global Health	Compositions for the treatment of hypertension
CN112826937B (zh) *	2021-03-25	2022-03-22	山东大学齐鲁医院	艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4681893A (en) *	1986-05-30	1987-07-21	Warner-Lambert Company	Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) *	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5447922A (en) *	1994-08-24	1995-09-05	Bristol-Myers Squibb Company	α-phosphonosulfinic squalene synthetase inhibitors
IL118778A (en) *	1995-07-03	1999-07-14	Sankyo Co	Pharmaceutical compositions for the treatment of arteriosclerosis and xanthoma containing an hmg-coa reductase inhibitor
AU720853B2 (en) *	1995-11-02	2000-06-15	Warner-Lambert Company	Method and pharmaceutical composition for regulating lipid concentration

1998
- 1998-08-07 GT GT199800126A patent/GT199800126A/es unknown
- 1998-08-11 TR TR2000/00563T patent/TR200000563T2/xx unknown
- 1998-08-11 IL IL13396298A patent/IL133962A0/xx not_active IP Right Cessation
- 1998-08-11 EA EA200000012A patent/EA200000012A1/ru unknown
- 1998-08-11 CA CA002296723A patent/CA2296723A1/fr not_active Abandoned
- 1998-08-11 WO PCT/IB1998/001230 patent/WO1999011260A1/fr not_active Ceased
- 1998-08-11 CN CNA031430937A patent/CN1473567A/zh active Pending
- 1998-08-11 CN CN98808463A patent/CN1268053A/zh active Pending
- 1998-08-11 KR KR1020007001062A patent/KR20010022477A/ko not_active Ceased
- 1998-08-11 KR KR10-2003-7000672A patent/KR20030015394A/ko not_active Ceased
- 1998-08-11 AT AT98935250T patent/ATE285767T1/de not_active IP Right Cessation
- 1998-08-11 HU HU0004318A patent/HUP0004318A3/hu unknown
- 1998-08-11 JP JP2000508363A patent/JP2001514223A/ja not_active Withdrawn
- 1998-08-11 PL PL98339091A patent/PL339091A1/xx unknown
- 1998-08-11 CN CNA031430929A patent/CN1473566A/zh active Pending
- 1998-08-11 NZ NZ502280A patent/NZ502280A/xx unknown
- 1998-08-11 NZ NZ530630A patent/NZ530630A/en unknown
- 1998-08-11 YU YU2000A patent/YU2000A/sh unknown
- 1998-08-11 AU AU84589/98A patent/AU740424B2/en not_active Ceased
- 1998-08-11 ID IDW20000196A patent/ID24118A/id unknown
- 1998-08-11 BR BR9811556-1A patent/BR9811556A/pt not_active Application Discontinuation
- 1998-08-11 PT PT98935250T patent/PT1009400E/pt unknown
- 1998-08-11 DE DE69828413T patent/DE69828413T2/de not_active Expired - Fee Related
- 1998-08-11 KR KR10-2004-7019432A patent/KR20040106591A/ko not_active Ceased
- 1998-08-11 ES ES98935250T patent/ES2234134T3/es not_active Expired - Lifetime
- 1998-08-11 SK SK143-2000A patent/SK1432000A3/sk unknown
- 1998-08-11 EP EP98935250A patent/EP1009400B1/fr not_active Expired - Lifetime
- 1998-08-17 PA PA19988457901A patent/PA8457901A1/es unknown
- 1998-08-24 PE PE1998000769A patent/PE107099A1/es not_active Application Discontinuation
- 1998-08-26 MA MA25228A patent/MA26536A1/fr unknown
- 1998-08-26 TN TNTNSN98155A patent/TNSN98155A1/fr unknown
- 1998-08-26 UY UY25155A patent/UY25155A1/es not_active Application Discontinuation
- 1998-08-26 DZ DZ980205A patent/DZ2595A1/fr active
- 1998-08-27 AR ARP980104287A patent/AR016399A1/es unknown
- 1998-08-27 EG EG102598A patent/EG24678A/xx active
- 1998-08-27 CO CO98049139A patent/CO4970724A1/es unknown
- 1998-08-27 MY MYPI98003941A patent/MY121008A/en unknown
- 1998-08-27 AP APAP/P/1998/001332A patent/AP1191A/en active
- 1998-08-28 HR HR60/057,276A patent/HRP980474A2/hr not_active Application Discontinuation
- 1998-08-28 ZA ZA9807839A patent/ZA987839B/xx unknown
- 1998-09-30 SA SA98190603A patent/SA98190603B1/ar unknown
2000
- 2000-01-09 IL IL133962A patent/IL133962A/en unknown
- 2000-01-13 BG BG104075A patent/BG64724B1/bg unknown
- 2000-01-14 IS IS5341A patent/IS5341A/is unknown
- 2000-02-18 OA OA1200000040A patent/OA11291A/en unknown
- 2000-02-28 NO NO20000996A patent/NO323987B1/no unknown
2001
- 2001-10-23 US US10/045,329 patent/US20020099046A1/en not_active Abandoned
2003
- 2003-05-19 US US10/442,285 patent/US20030199492A1/en not_active Abandoned
2004
- 2004-07-22 JP JP2004214382A patent/JP2005041875A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AP1191A (en)	2003-07-19
KR20030015394A (ko)	2003-02-20
SA98190603B1 (ar)	2006-07-04
NZ530630A (en)	2005-05-27
AR016399A1 (es)	2001-07-04
GT199800126A (es)	2000-01-29
KR20010022477A (ko)	2001-03-15
PA8457901A1 (es)	2000-05-24
AU740424B2 (en)	2001-11-01
CN1473566A (zh)	2004-02-11
JP2005041875A (ja)	2005-02-17
MY121008A (en)	2005-12-30
ZA987839B (en)	2000-02-28
IL133962A0 (en)	2001-04-30
YU2000A (sh)	2002-12-10
SK1432000A3 (en)	2000-12-11
NZ502280A (en)	2002-11-26
CN1268053A (zh)	2000-09-27
DE69828413D1 (de)	2005-02-03
CN1473567A (zh)	2004-02-11
UY25155A1 (es)	2000-12-29
DE69828413T2 (de)	2005-12-08
PE107099A1 (es)	1999-11-06
IS5341A (is)	2000-01-14
CA2296723A1 (fr)	1999-03-11
EP1009400A1 (fr)	2000-06-21
OA11291A (en)	2003-08-25
DZ2595A1 (fr)	2003-02-22
ID24118A (id)	2000-07-06
AP9801332A0 (en)	1998-09-30
US20020099046A1 (en)	2002-07-25
EP1009400B1 (fr)	2004-12-29
PL339091A1 (en)	2000-12-04
AU8458998A (en)	1999-03-22
JP2001514223A (ja)	2001-09-11
MA26536A1 (fr)	2004-12-20
BG64724B1 (bg)	2006-01-31
HUP0004318A2 (hu)	2001-05-28
KR20040106591A (ko)	2004-12-17
TNSN98155A1 (fr)	2005-03-15
EG24678A (en)	2010-04-27
TR200000563T2 (tr)	2000-07-21
BG104075A (en)	2000-09-29
HUP0004318A3 (en)	2002-10-28
PT1009400E (pt)	2005-02-28
CO4970724A1 (es)	2000-11-07
ES2234134T3 (es)	2005-06-16
EA200000012A1 (ru)	2000-08-28
BR9811556A (pt)	2000-08-22
NO20000996D0 (no)	2000-02-28
WO1999011260A1 (fr)	1999-03-11
ATE285767T1 (de)	2005-01-15
US20030199492A1 (en)	2003-10-23
NO20000996L (no)	2000-04-27
HRP980474A2 (en)	1999-06-30
IL133962A (en)	2006-07-05

Publication	Publication Date	Title
NO323987B1 (no)	2007-07-30	Farmasoytisk sammensetning og produkt omfattende atorvastatin, anvendelse derav, samt sett
EP1491193B1 (fr)	2006-07-12	Combinaisons thérapeutiques contenant de l'amlodipine et de l'atorvastatine
AP1207A (en)	2003-09-20	Combination therapy.
EP1180097B1 (fr)	2007-07-18	Sel commun d'amlodipine et d'atorvastatine
US20040248948A1 (en)	2004-12-09	Combination therapy
MXPA02009662A (es)	2003-03-10	Agentes antihipertensivos y su uso.
MXPA00002087A (en)	2001-12-04	Therapeutic combinations comprising amlodipin and atorvastatin
SA98190566B1 (ar)	2006-05-20	إتحادات علاجية تشمل أملوديبين amlodipine وأتورفاستاتين atorvastatin